Does IFN-α improve outcome of CML in the TKI era?
Dr Franck-Emmanuel Nicolini, Centre Hospitalier Universitaire de Lyon, France 

• LSC persistence on TKI
• IFN-α anti-tumorigenic activities
• IFN-α alone and CML: last clinical data
• What do we know nowadays about the combination of IFN-α and TKI?
• IFN-α alone as maintenance therapy?
• Conclusions